---
title: "Roivant Sciences: $1.4 Billion in Insider Sales — All Four Exit to Zero Shares"
type: news
slug: roivant-sciences-1-4-billion-insider-sales-all-four-exit-zero-2026
canonical_url: https://13finsight.com/news/roivant-sciences-1-4-billion-insider-sales-all-four-exit-zero-2026
published_at: 2026-02-28T21:31:38.893Z
updated_at: 2026-02-28T21:31:39.606Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 351
locale: en
source: 13F Insight
---

# Roivant Sciences: $1.4 Billion in Insider Sales — All Four Exit to Zero Shares

> Four Roivant Sciences insiders have generated $1.41 billion in combined sales. Hedge fund manager Daniel Gold ($619M), QVT Financial ($578M), Keith Manchester ($170M), and President Sukhatme ($45M) all hold zero shares.

Four insiders at Roivant Sciences (ROIV) have sold a combined $1.41 billion in stock — and every single one of them now holds zero shares. The biotech-focused "vant" platform company has seen its most prominent backers completely exit. Daniel Gold: The $619 Million Exit Hedge fund manager Daniel Allen Gold leads the group with a staggering $619.4 million in career sales across 228 transactions. His recent selling wave of $149.8 million brought his holdings to zero. Gold, who manages QVT Financial, was one of Roivant's earliest and largest backers — and has now fully monetized that bet. QVT Financial: $578 Million QVT Financial LP, Gold's investment vehicle, separately recorded $578.5 million in sales across 209 transactions. The recent $126.9 million in sales completed the fund's exit. Between Gold's personal account and QVT, the combined exit exceeds $1.19 billion from a single investment thesis. The Complete Exit Insider / EntityCareer SalesTransactionsRecent SalesShares After Daniel Allen Gold$619.4M228$149.8M0 QVT Financial LP$578.5M209$126.9M0 Keith S. Manchester$169.6M57$103.9M0 Mayukh Sukhatme$45.1M43$45.1M0 Keith Manchester: $170 Million Keith S. Manchester has sold $169.6 million across 57 transactions, with a massive $103.9 million in recent sales clearing his entire position. Manchester has been deeply involved with Roivant's "vant" model — the strategy of launching multiple subsidiary biotech companies under a shared platform. President Exits With $45 Million President and CIO Mayukh Sukhatme rounds out the quartet with $45.1 million in career sales across 43 transactions — notably, all of it in recent sales, suggesting a rapid, concentrated exit rather than gradual diversification. Like the others, Sukhatme holds zero shares. What $1.4 Billion in Exits Means Roivant's market cap is approximately $10 billion. The $1.41 billion in insider sales represents roughly 14% of the company's entire current value being extracted by just four insiders. With the company's highest-conviction backers completely exited, the ownership structure has fundamentally shifted. The Roivant model — incubating subsidiary biotechs like Dermavant, Immunovant, and Proteovant — requires long-term capital commitment. The complete exit of its most prominent insiders raises questions about whether the remaining portfolio of "vants" justifies current valuations. View all Roivant insider activity at ROIV stock page.

---

Source: 13F Insight — https://13finsight.com/news/roivant-sciences-1-4-billion-insider-sales-all-four-exit-zero-2026
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-02-28T21:31:39.606Z